ABCL635 Shows Promise for Menopausal Hot Flashes in Phase 2 Trial
A new nonhormonal treatment targeting the neurokinin 3 receptor significantly reduced the frequency and severity of menopausal hot flashes in a Phase 2 trial.
A new nonhormonal treatment targeting the neurokinin 3 receptor significantly reduced the frequency and severity of menopausal hot flashes in a Phase 2 trial.
CBT tailored for menopause may improve insomnia, hot flashes, and mood. New research highlights benefits—and the need for strategies to sustain improvements over time.
Sleep disturbance is common in peri- and postmenopausal women, even in the absence of VMS, and is independently linked to worse quality of life, depression, and anxiety.
Current guidelines list gabapentin as a recommended nonhormonal therapy for vasomotor symptoms in women who cannot or prefer not to use hormone therapy.
In this episode of It’s Not a Crisis, Dr. Lee Cohen speaks with host Doryn Wallach about the struggles many women experience during the menopausal transition. For most women, menopausal symptoms are manageable, but for [...]
CBT is effective for the management of vasomotor symptoms, depression, and sleep in perimenopausal women.
As women transition into the menopause, they experience a constellation of symptoms including vasomotor symptoms (hot flashes and night sweats), sleep disruption, problems with sexual functioning, and cognitive impairment. Women may also be more [...]
Stimulation of NKB-neurokinin 3 receptor (NK3R) signalling can induce hot flashes
About 80% of women experience vasomotor symptoms (VMS) – hot flashes and night sweats — as they transition into the menopause phase. For most, the symptoms are manageable, but for a sizeable subset of midlife [...]
While we have identified various sociodemographic variables as factors which modulate vulnerability to menopausal symptoms, no studies (to my knowledge) have looked at how a history of intimate partner violence (IPV) or other traumatic exposures [...]